Effects of Pulmonary Rehabilitation on Quality of Life and Health in Pulmonary Arterial Hypertens… (NCT06973382) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Effects of Pulmonary Rehabilitation on Quality of Life and Health in Pulmonary Arterial Hypertension Patients
84 participantsStarted 2025-05-20
Plain-language summary
Pulmonary hypertension (PH) is a major global health concern, affecting approximately 1% of the world's population. With global aging and increased life expectancy, its incidence continues to rise. PH is a progressive and disabling disease, with studies showing its progression correlates with worsening symptoms and increased mortality. Even with targeted medications, the prognosis remains poor across PH subtypes, with PAH patients showing only a 49% 7-year survival rate. The 2022 ESC/ERS guidelines emphasize that PH management requires a comprehensive, multidisciplinary approach. Beyond pharmacological and surgical treatments, rehabilitation has demonstrated benefits in improving exercise capacity, quality of life, functional class, and peak oxygen consumption. However, research on specific and effective comprehensive pulmonary rehabilitation programs remains lacking.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:Confirmed PH Diagnosis:
Right heart catheterization-confirmed pulmonary hypertension
Meets 2022 ESC/ERS Guidelines diagnostic criteria for:
* Group 1 (PAH) or
* Group 4 (CTEPH/other pulmonary artery obstructions)
Stabilized Treatment Status:
Group 1 (PAH): Received ≥3 months of targeted drug therapy
Group 4 (CTEPH): Completed ≥6 sessions of BPA\* or reached therapeutic endpoint
Functional Capacity:
WHO Functional Class I-III
Age: ≥18 years
Consent: Willing to provide written informed consent -
Exclusion Criteria:Physical Limitations:
Unable to perform pulmonary rehabilitation exercises due to disability or congenital malformations
Cardiopulmonary Testing Contraindications:
Medically unfit to complete CPET (cardiopulmonary exercise testing) after evaluation
Poor Compliance:
History of non-adherence making protocol completion unlikely
Life Expectancy:
Prognosis ≤1 year
\-
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.